ContraFect Corporation Announces Poster Presentation at the ICAAC/ICC 2015 Meeting for CF-301 for the Treatment of Staph Aureus Infections, Including MRSA
First Lysin Allowed by the FDA to Enter Human Clinical Trials
YONKERS, NY -- (Marketwired) -- 09/09/15 -- ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ), a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics and antibody products for life-threatening, drug-resistant infectious diseases, today announced that it will present new preclinical data for its lead compound CF-301 in a poster presentation at the ICAAC/ICC 2015 conference September 17-21, 2015 in San Diego, CA.
The company will present preclinical findings on CF-301, which is currently in Phase I development for the treatment of Staph aureus bloodstream infections, including MRSA. The abstract summarizing the data is published on the ICAAC/ICC website and is available to conference registrants at: http://www.abstractsonline.com/plan/start.aspx
Details of the poster presentation are as below:
Presentation Title: Lysin CF-301 Activates Daptomycin in Pulmonary Surfactant in vitro and Rescues Mice from Lethal Staphylococcal Pneumonia
Session Day & Time: Friday, September 18, 2015 12:00 PM - 2:00 PM PT
Location: Exhibit Hall F/San Diego Convention Center
Poster Number: F-290b
Session Title: New Agents and Approaches Addressing Gram-Positive Pathogens, including Mycobacteria
CF-301 is a bacteriophage lysin with potent activity against Staph aureus infections. CF-301 has the potential to be a first-in-class treatment for Staph bacteremia as it has a new mechanism of action for eliminating bacteria. It has specific and rapid bactericidal activity against Staph aureus and does not impact the body's good bacteria. By targeting a conserved region of the cell wall that is vital to bacteria, resistance is less likely to develop to CF-301. In vitro and in vivo experiments have shown that CF-301 clears biofilm. Combinations of CF-301 with standard of care antibiotics increased survival significantly in animal models of disease when compared to treatment with antibiotics or CF-301 alone. CF-301 was licensed from The Rockefeller University and developed at ContraFect.
ContraFect is a clinical-stage biotechnology company focused on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. Due to drug-resistant and newly emerging pathogens, hospital acquired infections are currently the fourth leading cause of death in the United States, following heart disease, cancer and stroke. ContraFect intends to address drug-resistant infections using its therapeutic product candidates from its lysin and monoclonal antibody platforms to target conserved regions of either bacteria or viruses (regions that are not prone to mutation). ContraFect's initial product candidates include new agents to treat antibiotic-resistant infections such as MRSA (drug-resistant staphylococcus bacteria) and influenza.
About the ICAAC/ICC 2015
ICAAC/ICC 2015 is a joint meeting of American Society for Microbiology (ASM)'s Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) and International Society of Chemotherapy (ISC)'s International Congress of Chemotherapy and Infection (ICC). ICAAC, the premier conference on antimicrobial agents and infectious diseases, showcases the latest-breaking science and lectures from top researchers from around the world. With over 60% of its attendees living outside of the United States, ICAAC provides a rare opportunity to bring together the field's foremost leaders to discuss the state of infection control and prevention on a global scale. Through oral and poster presentations, 10,000 physicians, clinical microbiologists, researchers, and pharmacists will come together to share their research, discover the latest breakthroughs, and work towards fostering global solutions to the problems of infectious diseases and antimicrobial agents.
This press release contains "forward-looking statements" within the meaning of the U.S. federal securities laws. Forward-looking statements can be identified by words such as "projects," "may," "will," "could," "would," "should," "believe," "expect," "anticipate," "estimate," "intend," "plan," "potential" or similar references to future periods. Forward-looking statements are statements that are not historical facts, nor assurances of future performance. Instead, they are based on ContraFect's current beliefs, expectations and assumptions regarding the future of its business, future plans, strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and changes in circumstances that are difficult to predict and many of which are beyond ContraFect's control, including those detailed in ContraFect's filings with the Securities and Exchange Commission. Specific forward-looking statements in this release include statements regarding our preclinical data that will be presented at ICAAC/ICC and our ability to address drug-resistant infections using our lysin and monoclonal antibody platforms to target conserved regions of either bacteria or viruses, all of which are subject to certain assumptions, risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Any forward-looking statement made by ContraFect in this press release is based only on information currently available and speaks only as of the date on which it is made. Except as required by applicable law, ContraFect expressly disclaims any obligations to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Source: ContraFect Corporation
Released September 9, 2015